Strong quarter driven by both organic growth and acquired assets Buy: Solid earnings growth momentum Buy: 9M17 results within expectations 1HFY18 results preview 3Q results core earnings up by 38%;reiterate Buy Consensus low; undemanding valuation; Buy re-iterated 3Q17: A solid top-line eroded by higher costs and D&A The war on entecavir, TDF and TAF Attractive entry, even if privatized;Upgrade to Buy 3Q17 result: some signs of cost pressure in Q4